US equities are ending the week with mixed sentiment. Stocks have been lower most of the week with Russia’s war and COVID-19 dampening investor outlook.
Oil down, gold down and Bitcoin (BTC) down.
Here are some of today’s trending stocks:
#Medavail Holdings Inc (NASDAQ: MDVL)
Medavail Holdings Inc (NASDAQ: MDVL) is a tech-enabled pharmacy, serving customers via a self-service pharmacy, mobile application, kiosk, and drive-thru solution
MDVL stock closed a private placement of $50m on Monday and the share price has since risen 45%.
Medavail Holdings is enjoying trader momentum and is up a further 41% in pre-market trading sitting at $2.
Over the past year, Medavail Holdings Inc (MDVL) has traded between $0.79 and $14.59.
#WD-40 Company (NASDAQ: WDFC)
WD-40 Company (NASDAQ: WDFC) reported its Q2 earnings yesterday. It cut its full-year profitability outlook on inflation pressure but also talked up its plans to raise prices. Investors are responding well as the WDFC share price climbs over 11% in pre-market trading.
The company also announced Steve Brass is going to be the next CEO of WD-40 Company. Steve will be the fifth CEO in WD-40’s 69-year history.
In Q2 the company reported net sales of $130m, up 16% Y/Y. The gross margin fell to 50% as input prices rose and it is focusing on restoring this to its target of 55%.
Net income came in at $19.5m, up 13% Y/Y.
Over the past year, WD-40 Company (WDFC) has traded between $170.44 and $321.41. Today it trades around $195.
Year-to-date, the WD-40 Company (WDFC) stock is down by -28.36% while the S&P 500 is down -6.18% over the same period of time.
#Aterian (NASDAQ: ATER)
Aterian (NASDAQ: ATER) is a leading consumer product platform. It builds, acquires and partners with brands to create top-selling consumer products via its technology. On April 6 it was described as the 166th Fastest Growing Company in Americas by the Financial Times.
The ATER share price is up 55% in the past five days and another 16% in pre-market trading.
Nevertheless, Aterian stock has also been subject to a short squeeze. Over the past year, Aterian Inc (ATER) has traded between $2.10 and $32.
#Biofrontera (NASDAQ: BFRI)
Biofrontera (NASDAQ: BFRI) stock is climbing in premarket trading. Investors appear to be pleased with BFRI’s Q4 and FY22 earnings report.
BFRI Financial Highlights
Q4 Total Revenues: $9.2m (up 7% Y/Y)
2021 Total Revenues: $24.1m (up 28% Y/Y)
Cash and cash equivalents: $24.5m as of December 31, 2021
Raised gross proceeds: $18m from IPO and $15m from private placement
The biopharmaceutical went public via IPO in October 2021. Its flagship product is Ameluz which is involved in various Phase 1, 2 and 3 studies for the treatment of actinic keratosis, a leading route to skin cancer.
Erica Monaco, Chief Executive Officer of Biofrontera Inc, said:
“2021 was a foundational year for Biofrontera Inc. From completing our IPO in October to laying the groundwork for expanding the label of our flagship product Ameluz®, I’m proud of the hard work by our team in executing Biofrontera’s strategic vision. We entered 2022 with the capital, commercial momentum and strategic plan in place to build shareholder value,”
#ENDRA Life Sciences Inc (NASDAQ: NDRA)
ENDRA Life Sciences Inc (NASDAQ: NDRA) share price is up 30% in early market trading. The company reported its Q4 and full year earnings a week ago and has since gained 54%. But today’s bump appears to come from a positive analyst rating and research report.
Vernon Bernardino, of HC Wainwright, published a report with a Buy rating and target share price of $5.
Over the past year, ENDRA Life Sciences Inc (NDRA) has traded between $0.34 and $2.63. Today it sits at $0.59.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care.